middl
east
respiratori
syndrom
coronaviru
merscov
emerg
import
viru
sinc
caus
multipl
outbreak
hospit
especi
kingdom
saudi
arabia
outsid
arabian
peninsula
sinc
emerg
merscov
total
case
includ
death
report
world
health
organ
due
increas
morbid
mortal
merscov
infect
attent
direct
toward
develop
prevent
strategi
establish
therapeut
modal
earlier
review
base
sever
acut
respiratori
syndrom
sar
experi
suggest
possibl
option
treatment
merscov
infect
review
provid
overview
progress
develop
therapeut
strategi
mer
search
pubm
embas
cochran
scopu
googl
scholar
use
follow
term
mer
merscov
middl
east
respiratori
syndrom
combin
treatment
therapi
also
review
refer
articl
includ
studi
report
identifi
search
classifi
studi
follow
categori
vivo
vitro
studi
anim
studi
human
case
report
case
seri
clinic
studi
grade
level
evid
base
oxford
centr
evidencebas
medicin
vitro
studi
show
variabl
activ
variou
agent
merscov
tabl
agent
includ
interferon
ribavirin
hiv
proteas
inhibitor
nelfinavir
ritonavir
lopinavir
interferon
antivir
type
ifn
system
major
part
innat
immun
respons
vitro
studi
show
uml
antimerscov
activ
higher
ifnunivers
type
respect
vitro
studi
show
lower
merscov
compar
ribavirin
nucleosid
analog
activ
host
kinas
nucleotid
shown
vitro
dose
ribavirin
requir
inhibit
merscov
replic
high
achiev
vivo
nelfinavir
lopinavir
inhibit
merscov
vitro
mean
effect
concentr
lopinavir
use
vero
cell
camostat
heptad
repeat
peptid
two
merscov
fusion
inhibitor
test
vitro
fusion
inhibitor
camostat
inhibit
viral
entri
human
bronchial
submucos
glandderiv
cell
immatur
lung
tissu
second
fusion
inhibitor
inhibit
merscov
replic
spike
proteinmedi
cellcel
fusion
cyclosporin
affect
function
mani
cyclophilin
act
chaperon
facilit
protein
fold
vitro
cyclosporin
inhibit
merscov
replic
nitazoxanid
broadspectrum
antivir
agent
teicoplanin
inhibitor
cathepsin
l
late
endosomelysosom
blocker
entri
merscov
also
show
inhibitori
effect
merscov
vitro
studi
evalu
variou
agent
therapi
merscov
anim
model
tabl
rhesu
macaqu
model
combin
decreas
viral
replic
within
h
merscov
infect
primat
model
mortal
rate
h
postinocul
reduc
untreat
anim
treat
combin
either
lopinavir
ritonavir
intranas
use
analog
improv
pharmaceut
properti
protect
mice
model
anim
model
use
merscov
infect
mice
use
high
titer
mer
immun
camel
serum
effect
reduc
lung
injuri
acceler
viru
clearanc
mycophenol
direct
indirect
antivir
activ
modul
ifn
respons
use
mycophenol
common
marmoset
anim
model
result
higher
mortal
untreat
anim
monoclon
antibodi
design
antibodi
deriv
larg
phagedisplay
antibodi
librari
b
cell
healthi
donor
use
mice
show
promis
result
therapeut
prophylact
agent
current
anim
model
complet
reflect
cours
merscov
diseas
human
thu
data
obtain
anim
model
interpret
cautious
anim
model
util
therapi
shortli
infect
base
analysi
sar
data
interferonribavirin
combin
suggest
possibl
therapeut
option
treatment
merscov
infect
limit
data
avail
regard
clinic
efficaci
antivir
agent
tabl
first
use
combin
ribavirininterferon
therapi
five
patient
mer
infect
therapi
start
late
cours
diseas
median
time
admiss
therapi
day
includ
patient
none
respond
therapi
subsequ
retrospect
cohort
studi
mer
patient
receiv
ribavirininterferon
compar
patient
surviv
rate
better
receiv
combin
therapi
vs
p
howev
surviv
rate
statist
differ
vs
tabl
anoth
case
seri
mer
patient
ribavirin
peginterferon
compar
studi
patient
respect
mortal
rate
statist
differ
two
group
vs
larg
cohort
studi
patient
variou
combin
interferon
ribavirin
use
differ
outcom
tabl
case
seri
patient
patient
receiv
ribavirin
interferonalfa
within
day
admiss
surviv
compar
patient
die
receiv
therapi
day
admiss
anoth
studi
evalu
use
interferon
beta
interferon
alpha
ribavirin
show
surviv
rate
respect
tabl
combin
therapi
also
use
case
report
tabl
role
combin
ribavirin
ifn
also
tri
treatment
prophylaxi
current
studi
use
ribavirin
ifn
combin
therapi
merscov
infect
reli
small
number
patient
trend
improv
thu
suggest
combin
type
interferon
ribavirin
could
use
due
inhomogen
natur
avail
studi
limit
data
avail
precis
recommend
therapi
mer
could
establish
combin
lopinavirritonavir
ribavirin
interferonalpha
use
one
case
one
patient
receiv
pegyl
interferon
ribavirin
lopinavirritonavir
day
ill
patient
continu
merscov
respiratori
tract
secret
fourth
week
ill
howev
viremia
detect
day
initi
tripl
therapi
case
seri
eight
patient
receiv
mycophenol
mofetil
surviv
sar
epidem
passiv
immunotherapi
neutral
antibodi
consid
therapeut
approach
multipl
antibodi
merscov
tabl
merscov
infect
product
larg
quantiti
merscov
neutral
human
polyclon
antibodi
possibl
use
gammairradi
wholekil
virion
vaccin
spike
protein
nanoparticl
vaccin
bovin
model
util
one
dose
antibodi
prevent
infect
mice
antibodi
effect
given
h
h
merscov
infect
corti
et
al
isol
potent
merscovneutr
antibodi
memori
b
cell
infect
individu
antibodi
bind
site
spike
protein
neutral
merscov
infect
antibodi
use
success
mice
model
similarli
util
human
mous
model
merscov
infect
antibodi
spike
protein
efficaci
prophylaxi
antibodi
obtain
sera
mer
immun
camel
support
clearanc
viru
reduct
sever
diseas
merscovinfect
mice
howev
purif
safeti
antibodi
human
establish
yet
cellular
dipeptidyl
peptidas
iv
ddp
iv
known
adenosin
deaminas
ada
complex
import
receptor
mediat
merscov
infect
viral
spike
protein
merscov
receptor
bind
domain
rbd
present
surfac
spike
protein
bind
host
cell
receptor
dpp
iv
human
dpp
iv
present
mainli
lower
respiratori
tract
area
bronchial
epitheli
alveolar
cell
although
ddp
iv
import
viral
entri
host
cell
use
dpp
iv
inhibitor
sitagliptin
vildagliptin
saxagliptin
block
infect
merscov
vitro
use
monoclon
antibodi
exhibit
possibl
human
mab
neutral
pseudoviru
live
viru
rhesu
model
merscov
infect
human
monoclon
antibodi
merscov
effect
reduc
patholog
merscov
use
polyclon
antibodi
pab
inhibit
merscov
infect
vitro
human
monoclon
antibodi
mab
mab
significantli
inhibit
merscov
infect
vitro
polyclon
antibodi
merscov
domain
neutral
viru
infect
mani
merscov
antibodi
develop
test
sar
epidem
convalesc
plasma
thought
improv
outcom
sar
patient
previou
studi
suggest
convalesc
plasma
may
use
patient
sar
sever
influenza
may
result
decreas
viral
load
lower
mortal
rate
howev
studi
low
low
qualiti
lack
control
group
risk
bia
two
patient
merscov
infect
receiv
intraven
immunoglobulin
attempt
treat
infect
one
patient
saudi
arabia
usa
protocol
use
convalesc
plasma
therapeut
option
mer
suggest
plasma
donor
identifi
antimerscov
indirect
immunofluoresc
assay
ifa
antibodi
titer
evid
activ
merscov
infect
nine
confirm
survivor
merscov
infect
posit
mer
antibodi
ifa
month
respect
two
patient
long
last
antibodi
sever
diseas
howev
titer
ifa
antibodi
measur
studi
larger
studi
merscov
neutral
antibodi
produc
low
level
shortliv
studi
kinet
merscov
antibodi
show
surviv
patient
fatal
case
produc
igg
neutral
antibodi
presenc
antibodi
lead
elimin
viru
lower
respiratori
tract
studi
patient
south
korea
nine
patient
titer
day
two
titer
day
studi
sampl
reactiv
elisa
result
reactiv
indirect
fluoresc
antibodi
microneutr
assay
titer
thu
use
convalesc
plasma
treatment
merscov
clinic
trial
may
challeng
due
small
pool
potenti
donor
suffici
antibodi
titer
base
sar
experi
author
suggest
steroid
therapi
might
benefici
sever
merscov
infect
corticosteroid
use
patient
sar
show
earli
use
corticosteroid
significantli
increas
viral
load
increas
risk
icu
admiss
mortal
anoth
studi
nonicu
patient
median
time
sarscov
becom
undetect
plasma
day
compar
day
patient
receiv
earli
corticosteroid
therapi
corticosteroid
use
adjunct
therapi
mani
patient
merscov
studi
patient
merscov
infect
one
patient
receiv
steroid
intraven
immunoglobulin
thrombocytopenia
initi
studi
five
patient
three
patient
receiv
combin
interferon
ribavirin
addit
adjunct
steroid
day
die
hospit
howev
steroid
evalu
systemat
therapi
mer
patient
host
proteas
furin
import
factor
break
region
merscov
vivo
studi
show
activ
multipl
agent
merscov
includ
chloroquin
chlorpromazin
cyclosporin
mycophenol
acid
addit
us
fda
approv
repurpos
agent
broad
antivir
activ
includ
vitro
activ
merscov
agent
includ
polymeras
inhibitor
helicas
inhibitor
spike
bind
immunoadhesin
mani
agent
current
preclin
investig
fluspirilen
thiothixen
fluphenazin
hydrochlorid
promethazin
hydrochlorid
astemizol
chlorphenoxamin
hydrochlorid
emerg
continu
case
merscov
infect
requir
avail
mer
therapi
urgent
need
develop
standard
anim
model
establish
standard
clinic
therapeut
protocol
current
clinic
studi
limit
case
report
case
seri
control
arm
qualiti
evid
studi
offer
low
make
conclus
difficult
draw
conclus
face
limit
studi
use
combin
therapi
interferon
ribavirin
develop
initi
develop
novel
therapeut
agent
repurpos
old
therapeut
agent
merscov
need
altern
pathway
test
clinic
trial
thought
convalesc
sera
may
provid
excit
altern
therapeut
agent
present
data
support
wide
adapt
therapi
current
mer
therapi
reli
support
care
provid
circulatori
ventil
support
expect
develop
use
repurpos
drug
would
allow
develop
therapeut
agent
merscov
best
locat
provid
random
control
trail
thought
intens
care
unit
use
convalesc
sera
presenc
milder
diseas
may
necessit
develop
therapeut
protocol
patient
sever
milder
diseas
monoclon
polyclon
antibodi
may
offer
therapeut
option
diseas
human
sinc
prospect
random
clinic
trial
low
due
sporad
natur
diseas
outsid
hospit
outbreak
prudent
wellconduct
prospect
clinic
studi
protein
involv
merscov
entri
replic
attract
target
develop
antivir
therapeut
clinic
studi
util
antimerscov
antibodi
therapeut
option
would
add
prospect
develop
therapeut
agent
syndrom
although
mani
drug
appear
effect
vitro
consider
avail
pharmacokineticpharmacodynam
properti
side
effect
taken
consider
medic
attract
use
lopinavir
interferon
mycophenol
among
agent
acceler
prefer
random
control
trail
conduct
neutral
antibodi
also
promis
use
agent
human
target
receptor
may
particular
import
howev
import
keep
mind
develop
mutat
bind
site
may
limit
use
agent
monoclon
antibodi
show
protect
efficaci
prophylaxi
anim
model
develop
test
monoclon
antibodi
associ
high
cost
lack
undefin
popul
use
monoclon
bodi
use
phase
clinic
trial
develop
agent
requir
time
cost
merscov
emerg
caus
multipl
hospit
outbreakscurr
licens
therapeut
agent
merscov
infectionmultipl
monoclon
polyclon
antibodi
develop
may
offer
therapeut
optionsrepurpos
old
drug
merscov
interest
strategi
deserv
develop
use
clinic
settingscurr
clinic
data
limit
case
report
case
seri
use
combin
antivir
medic
ribavirin
interferonth
combin
ribavirin
interferon
may
offer
surviv
advantag
day
daysanim
model
promis
delin
diseas
therapeut
optionsfurth
studi
includ
vitro
mechan
studi
enhanc
anim
model
merscov
infect
clinic
trial
evalu
combin
therapi
